FENC
Fennec Pharmaceuticals Inc.
Biotechnology · Healthcare · United States
12.06
close · 2026-08-13
value
50
cheaper than peers50
quality
68
stronger fundamentals68
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 12.67× | 68 |
| price to sales | 7.95× | 65 |
| price to book | 9.96× | 23 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -0.8% | 72 |
| revenue growth | 72.6% | 71 |
| return on equity | -52.7% | 34 |
3 of 4 measures available
Facts
| market cap | $423M |
| free cash flow | -$2.4M |
| employees | 35 |
| first trade | 2017-09-15 |
| next earnings | 2026-08-11 |
| fundamentals updated | 2026-08-11 |